Cargando…
Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers
Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had (11)C-PK11195 and (18)F-DOPA PET to assess microglial activation and striatal dopamine system...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359140/ https://www.ncbi.nlm.nih.gov/pubmed/32318850 http://dx.doi.org/10.1007/s00415-020-09830-3 |
_version_ | 1783558986417569792 |
---|---|
author | Gersel Stokholm, Morten Garrido, Alicia Tolosa, Eduardo Serradell, Mónica Iranzo, Alex Østergaard, Karen Borghammer, Per Møller, Arne Parbo, Peter Stær, Kristian Brooks, David J. Martí, Maria José Pavese, Nicola |
author_facet | Gersel Stokholm, Morten Garrido, Alicia Tolosa, Eduardo Serradell, Mónica Iranzo, Alex Østergaard, Karen Borghammer, Per Møller, Arne Parbo, Peter Stær, Kristian Brooks, David J. Martí, Maria José Pavese, Nicola |
author_sort | Gersel Stokholm, Morten |
collection | PubMed |
description | Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had (11)C-PK11195 and (18)F-DOPA PET to assess microglial activation and striatal dopamine system integrity, respectively. Comparisons were made with healthy controls. Five LRRK2-NMCs had subclinical reductions of putaminal (18)F-DOPA uptake. Three of them had significantly raised nigral (11)C-PK11195 binding bilaterally. These findings indicate that nigrostriatal dysfunction and neuroinflammation occur in LRRK2-NMCs. Studies in larger cohorts with appropriate follow-up are needed to elucidate the significance of neuroinflammation in the premotor phase of LRRK2-PD. |
format | Online Article Text |
id | pubmed-7359140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-73591402020-07-16 Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers Gersel Stokholm, Morten Garrido, Alicia Tolosa, Eduardo Serradell, Mónica Iranzo, Alex Østergaard, Karen Borghammer, Per Møller, Arne Parbo, Peter Stær, Kristian Brooks, David J. Martí, Maria José Pavese, Nicola J Neurol Original Communication Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had (11)C-PK11195 and (18)F-DOPA PET to assess microglial activation and striatal dopamine system integrity, respectively. Comparisons were made with healthy controls. Five LRRK2-NMCs had subclinical reductions of putaminal (18)F-DOPA uptake. Three of them had significantly raised nigral (11)C-PK11195 binding bilaterally. These findings indicate that nigrostriatal dysfunction and neuroinflammation occur in LRRK2-NMCs. Studies in larger cohorts with appropriate follow-up are needed to elucidate the significance of neuroinflammation in the premotor phase of LRRK2-PD. Springer Berlin Heidelberg 2020-04-21 2020 /pmc/articles/PMC7359140/ /pubmed/32318850 http://dx.doi.org/10.1007/s00415-020-09830-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Communication Gersel Stokholm, Morten Garrido, Alicia Tolosa, Eduardo Serradell, Mónica Iranzo, Alex Østergaard, Karen Borghammer, Per Møller, Arne Parbo, Peter Stær, Kristian Brooks, David J. Martí, Maria José Pavese, Nicola Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers |
title | Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers |
title_full | Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers |
title_fullStr | Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers |
title_full_unstemmed | Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers |
title_short | Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers |
title_sort | imaging dopamine function and microglia in asymptomatic lrrk2 mutation carriers |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359140/ https://www.ncbi.nlm.nih.gov/pubmed/32318850 http://dx.doi.org/10.1007/s00415-020-09830-3 |
work_keys_str_mv | AT gerselstokholmmorten imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT garridoalicia imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT tolosaeduardo imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT serradellmonica imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT iranzoalex imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT østergaardkaren imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT borghammerper imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT møllerarne imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT parbopeter imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT stærkristian imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT brooksdavidj imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT martimariajose imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers AT pavesenicola imagingdopaminefunctionandmicrogliainasymptomaticlrrk2mutationcarriers |